COMMUNIQUÉS West-GlobeNewswire

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024

13/08/2024 - 22:05

PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

13/08/2024 - 22:05

Enrollment Ongoing with FT819 1XX CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Single-agent Cyclophosphamide Included as Alternative Conditioning Regimen First Patient Treated with FT522 CAR NK Cell [...]

Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

13/08/2024 - 22:05

-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature [...]

Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

13/08/2024 - 22:05

Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and Biologicals Entered into a joint development agreement [...]

Asensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2024

13/08/2024 - 22:05

RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and [...]

NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

13/08/2024 - 22:05

-- Revenue grew to $19.3 million in Q2 2024, a 17% increase over Q2 2023 -- -- Increased full-year 2024 revenue guidance to $76 million to $78 million -- -- Demonstrated continued operating discipline as evidenced by [...]

Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

13/08/2024 - 22:05

Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 39 Investigative Sites Initiated In [...]

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

13/08/2024 - 22:05

– Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver topline data as [...]

BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update

13/08/2024 - 22:05

MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]

Better Choice Company Inc. Announces Second Quarter 2024 Results

13/08/2024 - 22:05

Net Income Increased 190% to $2.7 million Year-Over-Year E PS Growth of 170% to $2.98 Year-Over-Year Adjusted EBITDA Increased 98% to less than $(0.1) million 1 Year-Over-Year Recognized $3.6 million Gain on [...]

Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

13/08/2024 - 22:05

FDA advisory committee voted favorably that the data support arimoclomol as effective treatment for patients with NPC; PDUFA date of September 21, 2024 Pro forma June 30, 2024, cash, cash equivalents, investments and [...]

Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results

13/08/2024 - 22:05

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

13/08/2024 - 22:05

Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs Dosed the first patient in the Phase 1a clinical [...]

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13/08/2024 - 22:01

BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare [...]

Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

13/08/2024 - 22:01

Company to host conference call at 4:30 PM EDT today, Tuesday, August 13, 2024 SEATTLE and VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage [...]

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

13/08/2024 - 22:01

— Regulatory filing of first-in-human (FIH) trial of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) anticipated in the second half of 2024 — Preclinical data presented at the American Thoracic Society [...]

iCAD Reports Financial Results for Second Quarter Ended June 30, 2024

13/08/2024 - 22:01

NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast [...]

Teknova Reports Second Quarter 2024 Financial Results

13/08/2024 - 22:01

Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-Tek SM Production and RUO+ manufacturing grade Company [...]

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

13/08/2024 - 22:01

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis Preliminary clinical data from Ntrust-1 [...]